Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-/HR+), and triple negative breast cancer (TNBC). The prognoses of HER2-/HR+ and TNBC differ dramatically, as patients with TNBC progress more rapidly towards metastatic disease and only respond to chemotherapy agents. A large number of pipeline agents are being developed in HER2-/HR+ and/or TNBC, and are likely to change the treatment paradigm for these patients.
This report highlights the significant unmet need for expansion in the HER2- breast cancer marker across the eight major markets; it also discusses the associated commercial opportunities for new market entrants to gain a foothold in the market. GlobalData anticipates the HER2- breast cancer market to almost double, from $5.43B to $10.58B, over the forecast period of 2015-2025. The key drivers will be the incorporation of CDK4/6 inhibitors into the first-line metastatic setting and the rise of new targeted therapies and immunotherapies.
In 2015, the value of the HER2- breast cancer market in the 8MM was estimated to be $5.43B. This is forecast to grow to $10.58B by the end of the forecast period, with China the main driver of growth.
The largest driver will be the incorporation of premium priced CDK4/6 inhibitors into the first line setting. Pfizer’s Ibrance and Novartis’ ribociclib are expected to each reach blockbuster status by the end of the forecast period.
However, patent expiries of several blockbuster drugs and pricing difficulties are expected to limit growth in the HER2- breast cancer market over the forecast period.
Large market opportunities remain for the development of novel therapies in patients who acquire resistance to endocrine therapy.
Key topics covered in report
Prognosis for Breast Cancer
Triple Negative Breast Cancer
Global Breast Cancer Drug Forecast
Molecular Subtypes of Breast Cancer
Global Breast Cancer Drug Market Size
Global Breast Cancer Drug Market Share
Global Breast Cancer Drug Market Analysis
Global Breast Cancer Drug Market Research
For more coverage click on the link below:
Ankur Gupta, Head Marketing & Communications